Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) announced its quarterly earnings results on Tuesday. Here are the key takeaways from Bicara Therapeutics’ conference call:Get Bicara Therapeutics alerts:Management highlighted three-year follow-up data for FICERA in HPV-negative head and neck cancer, saying approximately one in three patients remained alive at three years—nearly double retrospective standard-of-care estimates—while maintaining a consistent safety profile. Bicara Therapeutics Price PerformanceShares of BCAX stock traded down $3.53 during trading hours on Tuesday, reaching $24.20. Bicara Therapeutics has a 12-month low of $9.67 and a 12-month high of $30.99. Read MoreReceive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.